Lantern Pharma Launches Zeta AI to Target Rare Cancers and Accelerate Drug Development

Lantern Pharma (NASDAQ: LTRN) introduces Zeta, an advanced AI platform designed to tackle one of medicine’s toughest challenges: rare and hard-to-treat cancers. Zeta leverages vast datasets to identify promising drug candidates, predict clinical outcomes, and streamline development pathways.

By reducing time, cost, and uncertainty in oncology research, Lantern aims to accelerate the delivery of precision therapies to patients with limited treatment options. Zeta represents a major step forward in using artificial intelligence to transform cancer drug development.

#LanternPharma
#LTRN
#ArtificialIntelligence
#CancerResearch
#RareDiseases
#Oncology
#DrugDevelopment
#PrecisionMedicine
#Biotech
#ClinicalTrials
#AIinHealthcare
#MedicalInnovation
#BiotechInvesting
#Pharmaceuticals
#Innovation